All Cancer articles – Page 23
-
NewsTumour metastasis is blocked by nanodiamonds
Carboxylic nanodiamonds could be a therapeutic agent for cancer, as melanoma cells treated with them showed little to no metastasis.
-
News
Understanding the genetic origins of disease variation
Researchers, using high-resolution mapping and mathematical modelling, have found mechanisms controlling mutation-driven diseases.
-
News
Discovery of molecular pathway could target lung cancer
New findings about how RBM10 inhibits lung cancer growth offers potential for an anti-cancer drug and more personalised treatment.
-
NewsPancreatic cancer initiates an immune system response
Studying pancreatic ductal adenocarcinoma tumours, researchers discovered 25 antibodies that responded to antigens.
-
NewsNew AI model can evaluate invasive breast cancer outcomes
Combining cancerous and non-cancerous cell patterns, the AI model evaluates breast cancer outcomes better than expert pathologists.
-
News
New contamination-detection test to improve T-cell therapy
Method to improve sterility assurance in biopharmaceutic manufacturing will lead to better patient outcomes.
-
NewsNoncoding RNA could be a new target for acute myeloid leukaemia
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
-
ArticleCombining autotaxin and TGF-β inhibitors in cancer
Dr Catherine Pickering, CEO of iOnctura, the clinical stage biopharmaceutical company delivering pioneering cancer treatments to patients with unmet medical needs, is at the forefront of cancer drug discovery. Dr Pickering and her team identify targets that have crucial roles in multiple tumour survival pathways, collaborate with world-renowned scientists and ...
-
NewsNew colon organoids better resemble both healthy and diseased colons
Researchers have developed organoids with naturally occurring early-stage immune cells, which could lead to effective personalised treatment.
-
News
Improving treatment response to KRAS inhibitors
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.
-
ArticleNovel technique to distinguish tumours from normal tissue
New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
-
ArticleCAR-NK cells: promising for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
-
NewsBreast cancer cells invade by a physical mechanism
Findings from using a 3D hydrogel to study how cancer cells physically tear the basement membrane offers promise for targeted treatment.
-
News
Targeting senescent macrophages: a potential cancer treatment
Using the nicotinamide mononucleotide molecule led to proliferation of non-senescent macrophages and lessened immunosuppressive factors.
-
NewsCancer and the DNA fork reversal mechanism
Researchers find that polymerase epsilon exonuclease is an essential target for cancer diagnosis and treatments that rely on DNA damage.
-
NewsNew technique to extract and analyse extracellular vesicles
Cellulose nanofiber sheets enable analysis of EVs, and miRNAs within them, offering potential for cancer treatment and personalised medicine.
-
NewsHow glucose restriction causes aggressive lung cancer phenotype
New understanding of how lung cancer cells become more aggressive when nutrient deprived could lead to novel combination treatments.
-
News
Potential new targets for chronic liver disease
Fatty liver disease treatments may become more effective after identification and greater understanding of more drug targets.
-
ArticleThe power of combinations in blood cancers
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers ...
-
NewsChemotherapy success calculated by new machine learning model
Percent necrosis calculated with machine learning model for patients with osteosarcoma provides an accurate prognosis for survival.